Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero‐Torres(Kirklin Clinic), Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Maria Corinna Palanca-Wessels(Unknown), Jerome H. Goldschmidt, Jonathan W. Friedberg(University of Rochester), Rodolfo Bordoni(Georgia Cancer Specialists), Beata Holkova(Virginia Commonwealth University), Yinghui Wang(Shanxi Medical University), Robert Chen(AstraZeneca (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Gregg A. Olsen(Providence Saint Joseph Medical Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center)
Cited by 142
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k